LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced that it has added Emmaus Life Sciences, Inc. (Emmaus) to its client roster. LHS provides strategic communications programming to Emmaus, helping to ensure all stakeholders “ including patients, healthcare practitioners, investors, and other audiences “ are educated and aware of sickle cell disease and Emmaus dedication to patients with this orphan disease.
Emmaus has a history rooted in scientific discovery. Endari„¢ (L-glutamine oral powder), approved in July 2017, was developed by Emmaus Chairman and CEO Yutaka Niihara, M.D., MPH. Dr. Niihara began researching the benefits of L-glutamine more than 25 years ago in 1992, as a physician treating sickle cell patients at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Today, the companys product pipeline includes the potential use of L-glutamine to treat diverticulosis, a GI condition affecting millions, as well as diabetes. In addition, Emmaus is researching cell-sheet technology for treatment of limbal stem-cell deficiency, an orphan disease.
We understand the importance of extending our visibility and building patient awareness of the treatment options for this debilitating orphan disease, commented Kurt Kruger, CFO of Emmaus Life Sciences. LHS, with its focus and expertise in the health and life science industry and connections with influencers, investment community and media make it the right partner for Emmaus.
We are honored to be working with Emmaus, a company led by Dr. Niihara that is truly passionate about patients and committed to medical innovation, said Donna L. LaVoie, President & CEO of LaVoieHealthScience. We are aligned with Emmaus passion to help patients afflicted with sickle cell disease and to raise the visibility of this disease, and the companys important contributions to this underserved patient community.
Indication Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.
Important Safety Information The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.
Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.
The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.
For more information, please see full Prescribing Information of Endari at: www.ENDARIrx.com/PI.
About LaVoieHealthScience LaVoieHealthScience provides public relations, investor relations, marketing, and digital communications to build recognition and value for health science innovators. The agency has received more than 30 awards during the past seven years in recognition of the work it has done for its industry-leading clients and was recently inducted into the 2018 Inc. 5000 Hall of Fame list of Fastest Growing Private Companies. LaVoieHealthScience represents public and privately-held leaders such as BIO, Carmell Therapeutics, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, SIRION Biotech, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies. For more information, please visit: https://lavoiehealthscience.com/
Katie Gallagher, 617-374-8800 x109
Manager, PR and Marketing